A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients : eortc trial 05971
A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients : eortc trial 05971
Publication date :
2008
Journal title :
Chronobiology International
ISSN :
0742-0528
eISSN :
1525-6073
Publisher :
Taylor & Francis, Philadelphia, United States - Pennsylvania
Baron B, Legrand C, Lévi F, Hoctin-Boes G. (2001). Chronomodulation: Optimal time finding design. 22nd annual meeting of the Society for Clinical Trials. Controlled Clin. Trials 22:59S-60S.
Barrett RJ, Blessing JA, Homesley HD, Twiggs L, Webster KD. (1993). Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Am. J. Clin. Oncol. :16494-16496.
Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, Botta M, Tampellini M, Donadio M, Mancarella S, De Lena M, Alquati P, Dogliotti L. (2000). Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J. Clin. Oncol. 18:3370-3377.
Carlson RW, Anderson BO, Bensinger W, Cox CE, Davidson NE, Edge SB, Farrar WB, Goldstein LJ, Gradishar WJ, Lichter AS, McCormick B, Nabell LM, Reed EC, Silver SM, Smith ML, Somlo G, Theriault R, Ward JH, Winer EP, Wolff A. (2000). NCCN practice guidelines for breast cancer. Oncology (Williston Park) 14:33-49.
Delcambre C, Bourgois H, Veyret C, Levy C, Switsers O, Allouache D, Grellard JM, Leconte A, Delozier T. (2004). A phase I/II study of capecitabine (X) combined with oral vinorelbine (V) as first or second-line chemotherapy in patients (Pts) with locally advanced or metastatic breast cancer (MBC). Breast Cancer Res. Treat. 88:S68, abstract 1080, SABCS 2004, San Antonio, USA.
Dieras V, Extra JM, Bellissant E, Espie M, Morvan F, Pierga JY, Mignot L, Tresca P, Marty M. (1996). Efficacy and tolerance of vinorelbine and fluorouracile combination as first line chemotherapy of advanced breast cancer: Results of a phase II study using a sequential group method. J. Clin. Oncol. 14:3097-3104.
Fety R, Urien S, Milano G, Kerbrat P, Bonneterre J, Fargeot P, Fumoleau P. (2001). A phase I pharmacokinetic (PK) and pharmacodynamic (PD) analysis of UFT/leucovorin (LV) in combination with vinorelbine (V). Proc. Am. Soc. Clin. Oncol. 20:90a, abstract 355, ASCO Annual Meeting 2001.
Filipski E, Amat S, Lemaigre G, Vincenti M, Breillout F, Lévi F. (1999). Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice. J. Pharmacol. Exp. Ther. 289:231-235.
Filipski E, King VM, Li X, Granda TG, Mormont MC, Claustrat B, Hastings MH, Levi F. (2003). Disruption of circadian coordination accelerates malignant growth in mice. Pathol. Biol. (Paris). 51:216-219.
Filipski E, Innominato PF, Wu M, Li XM, Iacobelli S, Xian LJ, Levi F. (2005). Effects of light and food schedules on liver and tumor molecular clocks in mice. J. Natl. Cancer Inst. 97:507-517.
Focan C. (2002). Rythms of cancer chronotherapy. In Redfern P.H. (ed.) Biological clocks: Pharmaceutical and therapeutic implications. Pharmaceutical Press: London and Chicago, pp. 235-282.
Fu L, Lee CC. (2003). The circadian clock: Pacemaker and tumour suppressor. Nat. Rev. Cancer 3:350-361.
Fumoleau P, Deporte R, Kerbrat P, Bonneterre J, Fargeot P. (2000). UFT/leucovorin plus vinorelbine combination for advanced breast cancer. Oncology (Williston Park) 14:50-55.
Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Re GL, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Levi F. (2006). Phase III trial comparing four-day chronomodulated therapy versus two-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. J. Clin. Oncol. 24:3562-3569.
Gorbacheva VY, Kondratov RV, Zhang R, Cherukuri S, Gudkov AV, Takahashi JS, Antoch MP. (2005). From the cover: Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. PNAS. 102:3407-3412.
Granda TG, Liu XH, Smaaland R, Cermakian N, Filipski E, Sassone-Corsi P, Levi F. (2005). Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB J. 19:304-306.
Hastings MH, Reddy AB, Maywood ES. (2003). A clockwork web: Circadian timing in brain and periphery, in health and disease. Nat. Rev. Neurosci. 4:649-661.
Hrushesky WJ. (1985). Circadian timing of cancer chemotherapy. Science 228:73-75.
Kataja VV, Colleoni M, Bergh J. (2005). ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC). Ann. Oncol. 16(Suppl.1):i10-i12.
Lévi F. (2001). Circadian chronotherapy for human cancers. Lancet Oncol. 2:307-315.
Lévi F, Benavides M, Chevelle C, Le Saunier F, Bailleul F, Misset JL, Regensberg C, Vannetzel JM, Reinberg A, Mathé G. (1990). Chemotherapy of advanced ovarian cancer with 4-O-tetrahydropyranyl doxorubicin and cisplatin: A randomized phase II trial with an evaluation of circadian timing and dose intensity. J. Clin. Oncol. 8:705-714.
Lévi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP, Kunstlinger F, Lecouturier S, Scorps-Declere A. (1992). A chronopharmacologic phase II clinical trial with 5-fluorouracile, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 69:893-900.
Lévi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L, Iacobelli S, Adam R, Kunstlinger F, Gastiaburu J, Bismuth H, Jasmin C, Misset JL. (1994). Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J. Natl. Cancer Inst. 86:1608-1617.
Lévi F, Soussan A, Adam R. (1995). A phase I/II trial of five days continuous intraveinous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with colorectal cancer. J. Infus. Chemother. 5:153-158.
Lévi F, Zidani R, Misset JL. (1997). Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681-686.
Li XM, Vincenti M, Levi F. (2002). Pharmacological effects of vinorelbine on body temperature and locomotor activity circadian rhythms in mice. Chronobiol. Int. 19:43-55.
Lis CG, Grutsch JF, Wood P, You M, Rich I, Hrushesky WJ. (2003). Circadian timing in cancer treatment: The biological foundation for an integrative approach. Integr. Cancer Ther. 2:105-111.
Lokich J. (1985). Optimal schedule for 5-fluorouracil chemotherapy: Intermittent bolus or continuous infusion. Am. J. Clin. Oncol. 8:445-448.
Mormont MC, Lévi F. (2003). Cancer chronotherapy: Principles, applications, and perspectives. Cancer 97:155-169.
Natoli C, Salini V, Irtelli L, Martino MT, Garufi C, Grassadonia A, Fiorentino B, Iacobelli S. (1996). A phase I study of five-day continuous venous infusion of carboplatin at circadian rhythm-modulated rate compared with constant rate. Anticancer Res. 16:1275-1279.
Nole F, Catania C, Sanna G, Imadalou K, Munzone E, Adamoli L, Longerey B, Blanchot G, Goldhirsch A. (2006). Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann. Oncol. 17:322-329.
Sano M, Tokuda Y, Noguchi S, Aogi K, Saeki T, Tabei T, Hatake K, Fujii H. (2006). [A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]. Gan To Kagaku Ryoho 33:1091-1097.
Tampellini M, Filipski E, Lévi F. (1995). Circadian variation of vinorebine toxicity in mice. Chronobiol. Int. 12:195-198.
Touitou Y, Smolensky MH, Portaluppi F. (2006). Ethics, standards, and procedures of animal and human chronobiology research. Chronobiol. Int. 23:1083-1096.
You S, Wood PA, Xiong Y, Kobayashi M, Du-Quiton J, Hrushesky WJ. (2005). Daily coordination of cancer growth and circadian clock gene expression. Breast Cancer Res. Treat. 91:47-60.
